Related references
Note: Only part of the references are listed.Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna L. Attia et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Therapeutic Antisense Targeting of Huntingtin
Anne Smith et al.
DNA AND CELL BIOLOGY (2020)
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Jonathan J. Darrow et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A resurrection of aducanumab for Alzheimer's disease
Lon Schneider
LANCET NEUROLOGY (2020)
Antibodies to watch in 2020
Helene Kaplon et al.
MABS (2020)
The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future
Heike J. Wobst et al.
MEDICINAL RESEARCH REVIEWS (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prey for the Proteasome: Targeted Protein Degradation-A Medicinal Chemist's Perspective
Laura M. Luh et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Gene editing and CRISPR in the clinic: current and future perspectives
Matthew P. Hirakawa et al.
BIOSCIENCE REPORTS (2020)
Antibiotics in the clinical pipeline in October 2019
Mark S. Butler et al.
JOURNAL OF ANTIBIOTICS (2020)
Antisense oligonucleotides for neurodegeneration
Blair R. Leavitt et al.
SCIENCE (2020)
Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data
Christopher P. Tinworth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Youhai Jiang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Critical analysis of antibacterial agents in clinical development
Ursula Theuretzbacher et al.
NATURE REVIEWS MICROBIOLOGY (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19 Therapeutic Options Under Investigation
Malak Kaddoura et al.
FRONTIERS IN PHARMACOLOGY (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2020)
Targeted degraders clear first safety hurdles
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2020)
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
COVID-19: A review of the proposed pharmacological treatments
Sarah Lam et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs
Michael D. Shultz
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal
Bennett Doughty et al.
ANNALS OF PHARMACOTHERAPY (2019)
A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers
Melicent Peck et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®
James G. Taylor et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Strategies to Address Challenges in Neuroscience Drug Discovery and Development
Patricio O'Donnell et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
Lin Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
ATM in DNA repair in cancer
Mei Hua Jin et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
Guy El Helou et al.
INFECTION AND DRUG RESISTANCE (2019)
An evaluation of benznidazole as a Chagas disease therapeutic
Ivo S. Caldas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Jong Wook Lee et al.
BLOOD (2019)
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Yuji Ogawa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Rick Brown
Rick Brown
NATURE REVIEWS DRUG DISCOVERY (2019)
Top product forecasts for 2019
Lisa Urquhart
NATURE REVIEWS DRUG DISCOVERY (2019)
The market for migraine drugs
Angela M. Sparrow et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Doubts persist for claimed Alzheimer's drug
Kelly Servick
SCIENCE (2019)
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
Tricia R. Cottrell et al.
CANCER JOURNAL (2018)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Robert J. Young et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Dean G. Brown et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Moxidectin for deworming: from trials to implementation
Mathieu Maheu-Giroux et al.
LANCET INFECTIOUS DISEASES (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Paul Morgan et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Thomas O. Carpenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review
Cedric Rossi et al.
TARGETED ONCOLOGY (2018)
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
Sohita Dhillon
DRUGS (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Brinda Emu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea
Stephanie N. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
Thomas J. Hwang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Koji Abe et al.
LANCET NEUROLOGY (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
Clinical trial cycle times continue to increase despite industry efforts
Linda Martin et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Opportunistic Infections in Biological Therapy, Risk and Prevention
Paul A. Bryant et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2017)
Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
Alessandra Mangia et al.
ANNALS OF GASTROENTEROLOGY (2017)
A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria
Fiona Macintyre et al.
BMC MEDICINE (2017)
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch
H. Scheerens et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Bradley C. Doak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
Aung Pyae Phyo et al.
LANCET INFECTIOUS DISEASES (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
Robert C. Griggs et al.
NEUROLOGY (2016)
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat
D. P. Germain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FDA Approval of Flibanserin - Treating Hypoactive Sexual Desire Disorder
Hylton V. Joffe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria
Nicholas J. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
Gillian M. Keating
DRUGS (2015)
ESKAPEing the labyrinth of antibacterial discovery
Ruben Tommasi et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Molecular Property Design: Does Everyone Get It?
Paul D. Leeson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
Aaron S. Kesselheim et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The evolution of the regulatory framework for antibacterial agents
John H. Rex et al.
ANTIMICROBIAL THERAPEUTICS REVIEWS: INFECTIOUS DISEASES OF CURRENT AND EMERGING CONCERN (2014)
Sofosbuvir: First Global Approval
Gillian M. Keating et al.
DRUGS (2014)
Neurodegenerative disease: Brain windfall
Katharine Gammon
NATURE (2014)
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
David Cook et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Drug Development and FDA Approval, 1938–2013
Jonathan J. Darrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration The Class of 2008
Thomas J. Moore et al.
JAMA INTERNAL MEDICINE (2014)
Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry
Hannah Koyfman
BIOTECHNOLOGY LAW REPORT (2013)
The current development of CNS drug research
Gregers Wegener et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease
Anita Y. M. Howe et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2013)
CD19 as an attractive target for antibody-based therapy
Ohad Hammer
MABS (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model
David W. Kang et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2012)
The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase
Thomas Goldner et al.
JOURNAL OF VIROLOGY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Fabry disease
Dominique P. Germain
ORPHANET JOURNAL OF RARE DISEASES (2010)
Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Edsel Maurice T. Salvana et al.
CLINICAL MICROBIOLOGY REVIEWS (2009)
Are development times for pharmaceuticals increasing or decreasing?
S Keyhani et al.
HEALTH AFFAIRS (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Share Paper
